Potent host-directed small-molecule inhibitors of myxovirus rna-dependent rna-polymerases

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Krumm, Stefanie A ^a,b   Ndungu, J Maina ^c   Yoon, Jeong Joong ^a,b   Dochow, Melanie ^a,b   Sun, Aiming ^c   Natchus, Michael ^c   Snyder, James P ^c   Plemper, Richard K ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JMN 3 003; JMN 5 165; JMN 5 166; N (4 METHOXYPHENYL) 2 NITROANILINE; RNA DIRECTED RNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; RNA DIRECTED RNA POLYMERASE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; HIGH THROUGHPUT SCREENING; HOST RANGE; HUMAN; HUMAN CELL; INFLUENZA VIRUS; NONHUMAN; ORTHOMYXOVIRUS; PARAMYXOVIRUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN SYNTHESIS; RNA SYNTHESIS; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; CHEMISTRY; COENZYME; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY;

MAMMALIA; ORTHOMYXOVIRIDAE; PARAMYXOVIRIDAE;

ANTIVIRAL AGENTS; COENZYMES; DRUG RESISTANCE, VIRAL; HUMANS; ORTHOMYXOVIRIDAE; RNA REPLICASE; VIRUS REPLICATION;

EID: 79956125738     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020069     Document Type: Article

References (83)

1. Lamb RA, Parks GD, (2007) Paramyxoviridae: The viruses and their replication. In: Knipe DM, Howley PM, editors. Fields Virology. 5 ed Philadelphia Wolters Kluwer/Lippincott Williams & Wilkins pp. 1449-1496.
2. Stiver G, (2003) The treatment of influenza with antiviral drugs. Cmaj 168: 49-56.
3. WHO (2004) http://www.who.int/whr/2004/en/09_annexes_en.pdf.
4. Leung AK, Kellner JD, Johnson DW, (2004) Viral croup: a current perspective. J Pediatr Health Care 18: 297-301.
5. Fry AM, Curns AT, Harbour K, Hutwagner L, Holman RC, et al. (2006) Seasonal trends of human parainfluenza viral infections: United States, 1990-2004. Clin Infect Dis 43: 1016-1022.
6. De Clercq E, (2006) Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5: 1015-1025.
7. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, et al. (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364: 759-765.
8. Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, et al. (2007) Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 44: 197-202.
9. Anderson LJ, Parker RA, Strikas RL, (1990) Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J Infect Dis 161: 640-646.
10. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, et al. (1993) Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 329: 1524-1530.
11. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, et al. (1997) Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176: 1215-1224.
12. Drake JW, (1993) Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A 90: 4171-4175.
13. Duffy S, Shackelton LA, Holmes EC, (2008) Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet 9: 267-276.
14. Schwegmann A, Brombacher F, (2008) Host-directed drug targeting of factors hijacked by pathogens. Sci Signal 1: re8.
15. Tan SL, Ganji G, Paeper B, Proll S, Katze MG, (2007) Systems biology and the host response to viral infection. Nat Biotechnol 25: 1383-1389.
16. Salerno D, Hasham MG, Marshall R, Garriga J, Tsygankov AY, et al. (2007) Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes. Gene 405: 65-78.
17. Schang LM, (2006) First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy. Expert Rev Anti Infect Ther 4: 953-956.
18. RxList (2011) RxList (2010) http://www.rxlist.com/tamiflu-drug.htm, last accessed January 2011.
19. Yoon JJ, Chawla D, Paal T, Ndungu M, Du Y, et al. (2008) High-throughput screening-based identification of paramyxovirus inhibitors. J Biomol Screen 13: 591-608.
20. White LK, Yoon JJ, Lee JK, Sun A, Du Y, et al. (2007) Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity. Antimicrob Agents Chemother 51: 2293-2303.
21. Garcia M, Yu XF, Griffin DE, Moss WJ, (2005) In vitro suppression of human immunodeficiency virus type 1 replication by measles virus. J Virol 79: 9197-9205.
22. Grant DM, (1991) Detoxification pathways in the liver. J Inherit Metab Dis 14: 421-430.
23. Koch-Weser J, (1974) Clinical application of the pharmacokinetics of procaine amide. Cardiovasc Clin 6: 63-75.
24. Moyle G, Boffito M, Stoehr A, Rieger A, Shen Z, et al. (2010) Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects. Antimicrob Agents Chemother 54: 3170-3178.
25. Zieve GW, Turnbull D, Mullins JM, McIntosh JR, (1980) Production of large numbers of mitotic mammalian cells by use of the reversible microtubule inhibitor nocodazole. Nocodazole accumulated mitotic cells. Exp Cell Res 126: 397-405.
26. Gao WY, Cara A, Gallo RC, Lori F, (1993) Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci U S A 90: 8925-8928.
27. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, et al. (1994) Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266: 801-805.
28. Lahusen T, De Siervi A, Kunick C, Senderowicz AM, (2003) Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential. Mol Carcinog 36: 183-194.
29. Engelking O, Fedorov LM, Lilischkis R, ter Meulen V, Schneider-Schaulies S, (1999) Measles virus-induced immunosuppression in vitro is associated with deregulation of G1 cell cycle control proteins. J Gen Virol 80 (Pt 7): 1599-1608.
30. Garcia M, Yu XF, Griffin DE, Moss WJ, (2008) Measles virus inhibits human immunodeficiency virus type 1 reverse transcription and replication by blocking cell-cycle progression of CD4+ T lymphocytes. J Gen Virol 89: 984-993.
31. Kuwano Y, Kim HH, Abdelmohsen K, Pullmann R Jr, Martindale JL, et al. (2008) MKP-1 mRNA stabilization and translational control by RNA-binding proteins HuR and NF90. Mol Cell Biol 28: 4562-4575.
32. Friedel CC, Dolken L, Ruzsics Z, Koszinowski UH, Zimmer R, (2009) Conserved principles of mammalian transcriptional regulation revealed by RNA half-life. Nucleic Acids Res 37: e115.
33. Sobell HM, (1985) Actinomycin and DNA transcription. Proc Natl Acad Sci U S A 82: 5328-5331.
34. Plemper RK, Erlandson KJ, Lakdawala AS, Sun A, Prussia A, et al. (2004) A target site for template-based design of measles virus entry inhibitors. Proc Natl Acad Sci U S A 101: 5628-5633.
35. Sun A, Yoon JJ, Yin Y, Prussia A, Yang Y, et al. (2008) Potent non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex. J Med Chem 51: 3731-3741.
36. Yoon JJ, Krumm SA, Ndungu JM, Hoffman V, Bankamp B, et al. (2009) Target analysis of the experimental measles therapeutic AS-136A. Antimicrob Agents Chemother 53: 3860-3870.
37. Boucrot E, Henry T, Borg JP, Gorvel JP, Meresse S, (2005) The intracellular fate of Salmonella depends on the recruitment of kinesin. Science 308: 1174-1178.
38. Cameron JE, Yin Q, Fewell C, Lacey M, McBride J, et al. (2008) Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways. J Virol 82: 1946-1958.
39. Coiras M, Camafeita E, Lopez-Huertas MR, Calvo E, Lopez JA, et al. (2008) Application of proteomics technology for analyzing the interactions between host cells and intracellular infectious agents. Proteomics 8: 852-873.
40. Hilpert K, Hancock RE, (2007) Use of luminescent bacteria for rapid screening and characterization of short cationic antimicrobial peptides synthesized on cellulose using peptide array technology. Nat Protoc 2: 1652-1660.
41. Honda A, (2008) Role of host protein Ebp1 in influenza virus growth: intracellular localization of Ebp1 in virus-infected and uninfected cells. J Biotechnol 133: 208-212.
42. Honda A, Okamoto T, Ishihama A, (2007) Host factor Ebp1: selective inhibitor of influenza virus transcriptase. Genes Cells 12: 133-142.
43. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, et al. (2008) Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 205: 585-594.
44. Taganov KD, Boldin MP, Baltimore D, (2007) MicroRNAs and immunity: tiny players in a big field. Immunity 26: 133-137.
45. Konig R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, et al. (2010) Human host factors required for influenza virus replication. Nature 463: 813-817.
46. Karlas A, Machuy N, Shin Y, Pleissner KP, Artarini A, et al. (2010) Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 463: 818-822.
47. Alvesalo J, Greco D, Leinonen M, Raitila T, Vuorela P, et al. (2008) Microarray analysis of a Chlamydia pneumoniae-infected human epithelial cell line by use of gene ontology hierarchy. J Infect Dis 197: 156-162.
48. Reghunathan R, Jayapal M, Hsu LY, Chng HH, Tai D, et al. (2005) Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome. BMC Immunol 6: 2.
49. Taganov KD, Boldin MP, Chang KJ, Baltimore D, (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 103: 12481-12486.
50. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D, (2007) MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A 104: 1604-1609.
51. Ding XR, Yang J, Sun DC, Lou SK, Wang SQ, (2008) Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs. Pharmacogenomics J 8: 61-70.
52. Kaur G, Roy I, (2008) Therapeutic applications of aptamers. Expert Opin Investig Drugs 17: 43-60.
53. Mairal T, Ozalp VC, Lozano Sanchez P, Mir M, Katakis I, et al. (2008) Aptamers: molecular tools for analytical applications. Anal Bioanal Chem 390: 989-1007.
54. Borghouts C, Kunz C, Groner B, (2008) Peptide aptamer libraries. Comb Chem High Throughput Screen 11: 135-145.
55. Grimm D, Kay MA, (2007) Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 117: 3633-3641.
56. Wu L, Belasco JG, (2008) Let me count the ways: mechanisms of gene regulation by miRNAs and siRNAs. Mol Cell 29: 1-7.
57. Fewell GD, Schmitt K, (2006) Vector-based RNAi approaches for stable, inducible and genome-wide screens. Drug Discov Today 11: 975-982.
58. Filipowicz W, Bhattacharyya SN, Sonenberg N, (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114.
59. Tao SC, Chen CS, Zhu H, (2007) Applications of protein microarray technology. Comb Chem High Throughput Screen 10: 706-718.
60. Fink J, Gu F, Ling L, Tolfvenstam T, Olfat F, et al. (2007) Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl Trop Dis 1: e86.
61. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49: 4721-4732.
62. Balzarini J, (2007) Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses? Antivir Chem Chemother 18: 1-11.
63. McGovern SL, Caselli E, Grigorieff N, Shoichet BK, (2002) A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem 45: 1712-1722.
64. Sun M, Fuentes SM, Timani K, Sun D, Murphy C, et al. (2008) Akt plays a critical role in replication of nonsegmented negative-stranded RNA viruses. J Virol 82: 105-114.
65. Ehrhardt C, Ludwig S, (2009) A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway. Cell Microbiol 11: 863-871.
66. Ehrhardt C, Wolff T, Pleschka S, Planz O, Beermann W, et al. (2007) Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. J Virol 81: 3058-3067.
67. Luthra P, Sun D, Wolfgang M, He B, (2008) AKT1-dependent activation of NF-kappaB by the L protein of parainfluenza virus 5. J Virol 82: 10887-10895.
68. Carsillo M, Kim D, Niewiesk S, (2010) Role of AKT kinase in measles virus replication. J Virol 84: 2180-2183.
69. Fisher MB, Rettie AE, (1997) Prochiral sufides probes for the active-site topography of rabbit flaving containing monooxygenase 2 (FMO2). Tetrahedron 8: 613-618.
70. Boyd DR, Sharma ND, Byrne BE, Haughey SA, Kennedy MA, et al. (2004) Dioxygenase-catalysed oxidation of alkylaryl sulfides: sulfoxidation versus cis-dihydrodiol formation. Org Biomol Chem 2: 2530-2537.
71. Kagan HB, (2000) Asymmetric Oxidation of Sulfides. In: Ojima I, editors. Catalytic Asymmetric Synthesis New York Wiley-VCH pp. 327-356.
72. Moyle G, Boffito M, Shen Z, Manhard K, Sheedy B, et al. (2008) RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, shows positive outcome in treatment of näive HIV patients. 48 Annual ICAAC/IDSA 46th Annual Meeting. Washington D.C.
73. Girardet J-L, Koh Y-H, de la Rosa M, Gunic E, Hong Z, et al. (2006) Preparation of S-triazolyl a-mercaptoacetanilides as inhibitors of HIV reverse transcriptase. In: Appl. PI, editors.
74. Ono N, Tatsuo H, Hidaka Y, Aoki T, Minagawa H, et al. (2001) Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol 75: 4399-4401.
75. Buchholz UJ, Finke S, Conzelmann KK, (1999) Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 73: 251-259.
76. Plemper RK, Doyle J, Sun A, Prussia A, Cheng LT, et al. (2005) Design of a small-molecule entry inhibitor with activity against primary measles virus strains. Antimicrob Agents Chemother 49: 3755-3761.
77. Spearman C, (1908) The method of right and wrong cases (constant stimuli) without Gauss's formula. Br J Phsychol 2: 227-242.
78. Plemper RK, Hammond AL, Gerlier D, Fielding AK, Cattaneo R, (2002) Strength of envelope protein interaction modulates cytopathicity of measles virus. J Virol 76: 5051-5061.
79. Organization WH, (2009) CDC protocol of realtime RTPCR for influenza A (H1N1) Atanta, GA, USA The WHO Collaborating Centre for influenza at CDC Atlanta, United States of America pp. 1-7.
80. Darzynkiewicz Z, (1990) Differential staining of DNA and RNA in intact cells and isolated cell nuclei with acridine orange. Methods in Cell Biology 33: 285-298.
81. Lee JK, Prussia A, Snyder JP, Plemper RK, (2007) Reversible inhibition of the fusion activity of measles virus F protein by an engineered intersubunit disulfide bridge. J Virol 81: 8821-8826.
82. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, et al. (1995) Rescue of measles viruses from cloned DNA. Embo J 14: 5773-5784.
83. Sidhu MS, Chan J, Kaelin K, Spielhofer P, Radecke F, et al. (1995) Rescue of synthetic measles virus minireplicons: measles genomic termini direct efficient expression and propagation of a reporter gene. Virology 208: 800-807.